FCG
DGX icon

Fielder Capital Group’s Quest Diagnostics DGX Stock Holding History

Fielder Capital Group’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,168
Closed -$203K – 297
2025
Q4 		$203K Buy
1,168
+28
+2% +$5.1K 0.04% 265
2025
Q3 		$217K Buy
+1,140
New +$202K 0.05% 236

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Fielder Capital Group's DGX Position: Q1 2026 in Review

Fielder Capital Group sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 1,168 shares — an estimated $203K sold.

Fielder Capital Group first reported a position in DGX in Q3 2025 and held it in 2 quarters. The position peaked at $217K in Q3 2025. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Fielder Capital Group reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Fielder Capital Group sold 1,168 Quest Diagnostics shares in Q1 2026, an estimated $203K.
  • Fielder Capital Group first reported a position in Quest Diagnostics in Q3 2025 and held it in 2 quarters.
  • Fielder Capital Group's Quest Diagnostics position peaked at $217K in Q3 2025.
  • 1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Fielder Capital Group's 13F filing for Q1 2026, filed 12 May 2026.